Lancashire and South Cumbria
Formulary
Formulary
2 Cardiovascular system
02-12 PCSK9 inhibitors
| Alirocumab Praluent® |
|
Formulary
|
Pre-filled pen 75mg, 150mg |
 NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
|
| Evolocumab Repatha® |
|
Formulary
|
Pre-filled pen 140mg primary hypercholesterolaemia or mixed dyslipidaemia in adults as per NICE TA394 |
|
NICE TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
|
|
| Evolocumab (Repatha®) |
|
Formulary
|
Prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin |
 LSCMMG: Evolocumab NMR |
|
Links
- EMA recommends withdrawal of Tredapative
Enoxaparin Shared Care Guideline **FOR USE IN THE MORECAMBE BAY REGION ONLY**- Low Molecular Weight Heparins - Use in Primary care Best Practice Guideline *FOR USE IN PENNINE REGION ONLY*
- LSC Statin Intolerance Pathway
- LSC Statin Intolerance Pathway
- LSCMMG - Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG - Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Atrial Fibrillation Pathway for the prevention of stroke and systemic embolism in AF in the absence of valvular heart disease
- LSCMMG: Evolocumab NMR
- LSCMMG: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia: Position Statement
- LSCMMG: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia: Position Statement
- LSCMMG: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia: Position Statement
- LSCMMG: Lipid Management Pathway for Primary Prevention of Cardiovascular Disease
- LSCMMG: Lipid Management Pathway for Secondary Prevention of Cardiovascular Disease
- LSCMMG: Low Molecular Weight Heparins (LMWHs) Summary Prescribing Guide
- MHRA: Clopidogrel and proton pump inhibitors: interaction—updated advice
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Fibrates: first-line treatment not recommended
- MHRA: Statins: interactions, and updated advice for atorvastatin
- MHRA: Statins: risk of hyperglycaemia and diabetes
- NG 185 - Acute coronary syndromes
- NG 196 - Atrial fibrillation: diagnosis and management
- NHSE: Clinical Commissioning Policy: Lomitapide for treating homozygous familial hypercholesterolaemia (adults) [1679]
- NHSE: Summary of national guidance for lipid management
- NICE HST13: Volanesorsen for treating familial chylomicronaemia syndrome
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG136: Hypertension in adults: diagnosis and management
- NICE NG187: Acute heart failure: diagnosis and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification
- NICE NG95: Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis
- NICE TA1002: Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over
- NICE TA385 - Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
- NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA394 - Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
- NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
- NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
- NICE: schizophrenia - omega-3 fatty acid medicines
- NICE: schizophrenia - omega-3 fatty acid medicines
- Renal: Enhanced Supportive Kidney Care Guideline
- UKMI Q & A: Review of evidence for dyslexia